Streetbeat News

Revenues

DBGI

Digital Brands Group (DBGI) has signed a letter of intent to open a retail store in March, with an expectation that the store will generate over $1.5 million in annual revenue.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:36 pm

PGY

Pagaya Technologies Ltd. has announced that its full-year 2023 network volume is expected to surpass the higher end of its previously forecasted range of $8 billion to $8.2 billion.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:29 pm

COYA

Coya Therapeutics has expanded its pipeline for COYA 302 to include treatments for Frontotemporal Dementia and Parkinson's Disease, due to the shared inflammatory pathways and Treg cell dysfunction in these diseases. COYA 302 is a combination immunotherapy targeting multiple pathways, potentially overcoming the immune challenges in these conditions. The company reassures its cash runway into 2026 and provides a positive update on milestones and catalysts for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:27 pm

AMSC

AMSC has received an $8 million order for 3 MW class wind turbine electrical control systems from Inox Wind. The order is a follow-on, with immediate delivery requested, and shipments expected throughout 2024. This order reflects the growing Indian wind market, where AMSC has been active for over a decade. AMSC's 3 MW class wind turbine design is certified to operate up to 3.3 MW under specific conditions, and under an exclusive license agreement, AMSC will be the sole ECS supplier for Inox's 3 MW class wind turbine in India.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:25 pm

AAPL

AMZN

GOOGL

IWM

META

MSFT

NVDA

SPY

TSLA

Institutional investors are optimistic about the U.S. economy avoiding a recession in 2024, with a majority expecting a soft or no landing. The 'Magnificent Seven' tech giants (Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla) are seen as a crowded but promising trade, especially with anticipated rate cuts by the Federal Reserve. Investors are also favoring U.S. equities, particularly small caps, as evidenced by the Russell 2000's outperformance compared to the S&P 500. The BofA survey shows a low expectation of a hard landing, with the Federal Reserve and corporate earnings being key market drivers for 2024.

Portfolio Pulse from Neil Dennis

January 16, 2024 | 1:25 pm

BMRA

Biomerica Inc. reported its Q2 2024 earnings with an EPS of $(0.9), an improvement from $(0.12) in the same quarter of the previous year. Revenue increased to $1.6 million from $1.5 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:25 pm

TM

Toyota Motor Corp (NYSE:TM) plans to produce a record 10.3 million vehicles in 2024, driven by high demand for its hybrid vehicles. The company is recovering from semiconductor shortages and aims to split production between 3.4 million in Japan and 6.9 million overseas. Toyota's electric vehicle production target is set at 250,000 for 2024 and 600,000 for 2025. A third of the 9.2 million vehicles sold in the first 11 months of 2023 were hybrids. TM shares saw a slight premarket drop of 0.35%.

Portfolio Pulse from Shivani Kumaresan

January 16, 2024 | 1:23 pm

DCTH

Delcath Systems has initiated the commercial use of its HEPZATO KIT for the treatment of metastatic uveal melanoma. This marks a significant milestone for the company as it begins to generate revenue from the product.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:13 pm

SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) has received FDA Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company, which focuses on precision genetic medicines for neuromuscular and cardiac diseases, also received Fast Track Designation last month. Patient dosing for the Phase 1/2 clinical trial of SGT-003 is expected to begin in mid-to-late Q1 2024. SGT-003 features a novel capsid and muscle tropic vector, which may offer improved transduction and muscle resiliency. The Orphan Drug Designation provides benefits such as financial incentives and the potential for seven years of market exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:08 pm

SLGG

Super League (NASDAQ: SLE) reported a record preliminary Q4 revenue of approximately $9.4 million, a 32% increase YoY, and annual revenues of about $25.0 million. The company anticipates profitability in 2024, backed by a record contract and pipeline expansion. Super League's CEO Ann Hand highlighted the company's growth, streamlined operations, and success in immersive 3D experiences on platforms like Roblox, Minecraft, and Fortnite. The company served almost 100 brands in 2023, with significant engagement and media coverage. Super League aims to transition from short-term campaigns to larger, recurring deals with notable clients like Visa, Disney, and Wal-Mart. The company raised $24.8 million and secured a $4.0 million accounts receivable facility, improving its balance sheet for future growth.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 1:07 pm